Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 1;64(2):477-483.
doi: 10.1093/rheumatology/keae500.

Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA

Man Fung Tsoi  1 , Lianne Kearsley-Fleet  1 , Narges Azadbakht  1 , Kath Watson  1 , Kimme L Hyrich  1   2 , James Bluett  2   3 ; BSRBR-RA Contributors Group
Collaborators, Affiliations

Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA

Man Fung Tsoi et al. Rheumatology (Oxford). .

Abstract

Objectives: Tocilizumab is an IL-6 receptor humanized monoclonal antibody for the treatment of rheumatoid arthritis (RA) with intravenous (IV) and subcutaneous (SC) preparations available. Only IV tocilizumab is dosed adjusting for weight. Therefore, we aimed to study the association between body weight and the effectiveness of tocilizumab by the route of administration.

Methods: Patients with RA-administered tocilizumab in the BSRBR-RA were included in the analysis and stratified by route of administration. Outcomes included the 6-month change in DAS28, the proportion of patients achieving DAS28 remission, 6-month EULAR response and persistence of the first route of tocilizumab administration. The exposure was every increase in 10 kg of body weight. Adjusted regression models appropriate to outcome were used to study the associations between body weight and outcomes. Multiple imputations accounted for missing data.

Results: A total of 2612 patients were included. Body weight was associated with reduced response to SC tocilizumab measured by change in DAS28: adjusted regression coefficient (95% CI) all patients 0.01 (-0.04, 0.07); IV: -0.03, (-0.1, 0.5); SC: 0.1 (0.02, 0.2) but not odds in achieving DAS28 remission or EULAR response. There was no significant association between body weight and the persistence of IV or SC tocilizumab.

Conclusion: Body weight was associated with the initial response to SC tocilizumab, although the difference in response was small, but not drug persistence. Physicians should monitor the body weight of patients and consider interventions to promote maintenance of a healthy weight.

Keywords: biological therapies; epidemiology; rheumatoid arthritis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Persistence of tocilizumab by baseline body weight
See this image and copyright information in PMC

References

    1. Saki A, Rajaei E, Rahim F. Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and meta-analysis of clinical trial studies. Reumatologia 2021;59:169–79. - PMC - PubMed
    1. Rubbert-Roth A, Aletaha D, Devenport J et al. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. Rheumatology (Oxford) 2021;60:682–91. - PMC - PubMed
    1. Kivitz A, Olech E, Borofsky M et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:1653–61. - PMC - PubMed
    1. Gardette A, Ottaviani S, Sellam J et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol 2016;35:857–61. - PubMed
    1. Pers YM, Godfrin-Valnet M, Lambert J et al. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol 2015;42:580–4. - PubMed

Publication types